Difference between revisions of "Bleomycin (Blenoxane)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex")
 
(46 intermediate revisions by 5 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.<ref name="insert">[[Media:Bleomycin.pdf | Bleomycin (Blenoxane) package insert (locally hosted backup)]]</ref>
+
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=4350 Bleomycin (Blenoxane) package insert]</ref><ref>[[:File:Bleomycin.pdf | Bleomycin (Blenoxane) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV, IM, SC, intrapleural
 
<br>Route: IV, IM, SC, intrapleural
−
<br>Extravasation: [[irritant]]
+
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference
 
*1 unit of bleomycin = 1 mg of bleomycin
 
*1 unit of bleomycin = 1 mg of bleomycin
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/bleomycin-342113 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://reference.medscape.com/drug/bleomycin-342113 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 +
 
 +
==Diseases for which it is used==
 +
*[[Carcinoma of unknown primary]]
 +
*[[Cutaneous basal cell carcinoma]]
 +
*[[Cutaneous squamous cell carcinoma]]
 +
*[[Diffuse large B-cell lymphoma]]
 +
*[[HIV-associated lymphoma]]
 +
*[[Classical Hodgkin lymphoma]]
 +
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
 +
*[[Kaposi sarcoma]]
 +
*[[Penile cancer]]
 +
*[[Post-transplant lymphoproliferative disorder]]
 +
*[[Testicular cancer]]
 +
 
 +
==Diseases for which it was used==
 +
*[[Follicular lymphoma]]
 +
*[[Head and neck cancer]]
 +
*[[Osteosarcoma]]
 +
*[[Small cell lung cancer]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/chemotherapy/drug-info/bleomycin.aspx Bleomycin (Blenoxane) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/bleomycin.aspx Bleomycin (Blenoxane) patient drug information (Chemocare)]</ref>
+
*[http://labeling.pfizer.com/ShowLabeling.aspx?id=4350 Bleomycin (Blenoxane) package insert]
 +
*[https://chemocare.com/druginfo/bleomycin.aspx Bleomycin (Blenoxane) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/bleomycin.aspx Bleomycin (Blenoxane) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/bleomycin-patient-drug-information Bleomycin (Blenoxane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bleomycin-patient-drug-information Bleomycin (Blenoxane) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/bleomycin-patient-drug-information Bleomycin (Blenoxane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bleomycin-patient-drug-information Bleomycin (Blenoxane) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
* 1973-07-31: Initial approval
 +
*2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: [[Head and neck cancer|squamous cell carcinoma of the head and neck]] (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); [[penile cancer|penis]]; [[cervical cancer|cervix]]; [[Vulvar cancer|vulva]]; [[Classical Hodgkin lymphoma|Hodgkin’s disease]]; [[:Category:Non-Hodgkin lymphomas|non-Hodgkin’s lymphoma]]; [[testicular cancer]] (including embryonal cell, choriocarcinoma, and teratocarcinoma). ''(No supporting studies are cited)''
 +
==History of changes in EMA indication==
 +
*1970-03-18: EURD
 +
 +
==Also known as==
 +
*'''Brand names:''' Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
+
[[Category:Intracavitary medications]]
−
[[Category:DNA synthesis inhibitors]]
+
[[Category:Intramuscular medications]]
−
[[Category:Irritant chemotherapy]]
+
[[Category:Intravenous medications]]
 +
[[Category:Subcutaneous medications]]
 +
[[Category:Irritant]]
 +
[[Category:Neutral]]
  
−
[[Category:Aggressive Non-Hodgkin lymphoma medications]]
+
[[Category:Antitumor antibiotics]]
−
[[Category:Basal cell and squamous cell skin cancer medications]]
+
[[Category:Human DNA synthesis inhibitors]]
−
[[Category:Bone cancer medications]]  
+
 
−
[[Category:Cancer of unknown primary medications]]  
+
[[Category:Carcinoma of unknown primary medications]]  
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Cutaneous basal cell carcinoma medications]]
 +
[[Category:Cutaneous squamous cell carcinoma medications]]
 +
[[Category:Diffuse large B-cell lymphoma medications]]
 +
[[Category:HIV-associated lymphoma medications]]
 +
[[Category:Classical Hodgkin lymphoma medications]]
 
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]]
 
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]]
 +
[[Category:Kaposi sarcoma medications]]
 
[[Category:Penile cancer medications]]  
 
[[Category:Penile cancer medications]]  
−
[[Category:Sarcoma medications]]  
+
[[Category:Post-transplant lymphoproliferative disorder medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Testicular cancer medications]]
 +
 +
[[Category:Follicular lymphoma medications (historic)]]
 +
[[Category:Head and neck cancer medications (historic)]]
 +
[[Category:Osteosarcoma medications (historic)]]
 +
[[Category:Small cell lung cancer medications (historic)]]
 +
 +
[[Category:FDA approved in 1973]]
 +
[[Category:EMA approved in 1970]]
 +
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 01:48, 29 June 2024

General information

Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1][2]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference

  • 1 unit of bleomycin = 1 mg of bleomycin

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1973-07-31: Initial approval
  • 2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma of the head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); penis; cervix; vulva; Hodgkin’s disease; non-Hodgkin’s lymphoma; testicular cancer (including embryonal cell, choriocarcinoma, and teratocarcinoma). (No supporting studies are cited)

History of changes in EMA indication

  • 1970-03-18: EURD

Also known as

  • Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel

References

  1. ↑ 1.0 1.1 Bleomycin (Blenoxane) package insert
  2. ↑ Bleomycin (Blenoxane) package insert (locally hosted backup)
  3. ↑ Bleomycin (Blenoxane) patient drug information (Chemocare)
  4. ↑ Bleomycin (Blenoxane) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Bleomycin_(Blenoxane)&oldid=87464"